Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. - Wikidata - wikimedia - TriplyDB

Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.

Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.

http://www.wikidata.org/entity/Q33359653

about

Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific.Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.Sirolimus therapy following early cyclosporine withdrawal in transplant patients: mechanisms of action and clinical results.A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT.Herpes simplex and varicella zoster viruses: forgotten but not gone.A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients.Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy.Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium.Endothelial cell transforming growth factor-β receptor activation causes tacrolimus-induced renal arteriolar hyalinosis.Workshop on late renal allograft dysfunction.Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials.A prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantation.Chronic hepatitis C virus infection and post-liver transplantation diabetes mellitus.Long-term medical management of the liver transplant recipient: what the primary care physician needs to know.Cost-effectiveness of sirolimus therapy with early cyclosporin withdrawal vs. long-term cyclosporin therapy in Australia.Mycophenolate mofetil and sirolimus combination in renal transplantation.The role and value of sirolimus administration in kidney and liver transplantation.The current role of calcineurin inhibitors in posttransplant immunosuppression?Conversion to sirolimus therapy in kidney transplant recipients with new onset diabetes mellitus after transplantation.Nanomedicines in renal transplant rejection--focus on sirolimus Kidney transplantation: current issues and future prospects.Cyclosporin-A associated malignancy.Hypertension in dialysis and kidney transplant patients.Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients.Clinical application of mTORi based immunosuppression for renal transplantation in India.Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.Comparison of early and late conversion of sirolimus in experimental model of chronic cyclosporine nephropathy.Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation.Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.Induction sirolimus and delayed graft function after deceased donor kidney transplantation in the United States.Long-term immunosuppression, without maintenance prednisone, after kidney transplantation.An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency.The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study.Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.Decrease in sirolimus-induced proteinuria after switch to everolimus in a liver transplant recipient with diabetic nephropathy.Cyclosporine triggers endoplasmic reticulum stress in endothelial cells: a role for endothelial phenotypic changes and death.Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys.Prednisone-free maintenance immunosuppression-a 5-year experience.

P2860

Q30235260-019C76BD-1CE3-4D2D-B464-D692910B2B75 Q31108592-70452F51-2D48-4B62-B59F-D9678B208FB0 Q33376348-BB7A0500-C1FF-4A1B-BBFB-50E78034F74D Q33551422-C1A968D6-0658-4C49-860E-AF92C059E59F Q34613055-6B27EB31-215F-4D98-AB48-1B31ADE37AE0 Q34805919-149A8AF2-4126-4A1F-9E10-531806381178 Q35130521-3AFCE5A8-C973-4D04-B1A0-20AEDF97CE3B Q35823308-2109F7B0-FF16-47BB-ADC3-C99A86A957A3 Q36095003-5BEA69BA-1657-42D8-A555-B8071CEB2FD9 Q36155832-FE91CFB4-2091-4B3B-822A-75358D63D548 Q36155850-FAE94D64-7469-43F1-952B-4F69AEB46006 Q36183858-6150B299-EA6D-4EF0-8C22-85F663E3A1BA Q36307547-2E0FE34D-F990-42D1-9C16-CFD1C8BE1752 Q36399571-F1A3B462-F10D-45AE-B198-2CC2A8AE1044 Q36536752-92DC83B1-3963-42FC-AD5C-25D4831C85F3 Q36575992-F79F38B9-73B7-4E98-A53F-13BF3432A385 Q36652031-3BAD5533-52E2-4BA2-8639-A95DD454F8D5 Q36733784-83C0551E-E545-45C9-9E7D-4C1E48A31F1D Q36899502-7509EA9F-E951-4603-9417-50FC1693D658 Q36920414-A0925CD4-D6DF-4BBE-846A-EA8FD440999E Q36938148-FF109EFE-BF49-48FA-9DAA-B1F8089572A7 Q37247310-BF017991-A028-43DF-8E54-FD3ED1781FF0 Q37253882-262FE687-D0BC-404E-A67E-39FFDBEB549D Q37321421-0D0FD74D-75E3-4600-8E38-E9DBA38410F6 Q37929851-BDD4CA9E-5821-4B72-9BF6-EED195D64D23 Q38190678-2EB7C682-D34D-49FD-8DCB-5D117CD170D7 Q38668601-8D28F7B6-F299-46C8-8AA0-567192E2AF99 Q38914374-FC188F8F-85D3-4835-A738-097396747ABB Q40819318-E6D9C386-EE15-41C8-A59E-93B263FA54A7 Q42078849-BB3DD2F1-D752-4CDE-B6D3-83D085483C9F Q43984395-23250169-286B-44A0-9771-F4655CB7B789 Q44981183-AE34216B-1763-4B10-8C67-6307757AC8B4 Q45023761-BBC28F4C-9827-47A5-A658-09E7687BBE82 Q45230221-62A0AC85-9234-40E9-A75B-823948992421 Q45991438-FC4F6F89-4DFD-486E-A804-7FE072FEDE6D Q46007205-82A7F0C9-FA1D-4302-8765-4B673690598A Q46224052-3082E93D-7A38-46A2-AC48-181944C0FB38 Q46262369-7D5C7BA5-DF20-47D6-AF98-597601441533 Q46702750-92450076-0602-4583-A8D2-4F8B0B536A5D Q46702753-A8526324-2385-4F31-8DC5-D9452E0C2653

P2860

Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.

http://www.wikidata.org/entity/Q33359653

description

2004 nî lūn-bûn

@nan

2004 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի մարտին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.

@ast

Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.

@en

type

label

Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.

@ast

Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.

@en

prefLabel

Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.

@ast

Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.

@en

P1433

Q33359653-9B2C86C5-9736-4613-A3D1-B71F52D079C3

P1476

Q33359653-DE9B905E-8978-4E40-9B33-79E73C12E92E

P2093

Q33359653-0797F4C2-B917-4765-AD51-F564A2CFBBEC

Q33359653-10F81313-5018-46CB-A8FF-96948B9427CF

Q33359653-2534286E-B7BB-4F3E-8C1E-D11EDE8B6DA1

Q33359653-2DC35038-9006-4972-A5D1-A7745FDB42EE

Q33359653-56BBE94F-6099-4BE9-8168-419E997EA3C2

Q33359653-58675BE0-6DD2-4E09-8803-796683713707

Q33359653-8C3FF939-E76C-4D84-94EA-3D3C4C45CA56

Q33359653-B30869F8-E040-43D1-BDC7-1F7DFD89C95E

Q33359653-B32113E0-FDCC-4F5D-BD3B-1A89E17F46CD

Q33359653-D3729661-3ED3-43F2-A03A-041434318F48

P304

Q33359653-F80B3430-AC80-49A6-8550-07F9E18C791E

P31

Q33359653-0A43FA6E-511C-494E-87D6-7262593ECCE5

P356

Q33359653-AA83A1F5-9FF5-4A92-A00A-DDE71C83A10C

P433

Q33359653-5176CD21-D74B-421F-94D1-73611A5549E4

P478

Q33359653-EDFA29DD-F0C9-4BAD-B361-F3224186A799

P577

Q33359653-E7EB2A73-8AB6-4B2B-9F0D-4E14752F5E87

P698

Q33359653-263FBC64-1754-4290-9BF7-C271FD4A065D

P356

01.ASN.0000113248.59077.76

P1433

Journal of the American Society of Nephrology

P1476

Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.

@en

P2093

Francesco P Schena

http://www.w3.org/2001/XMLSchema#string

Henri Kreis

http://www.w3.org/2001/XMLSchema#string

James T Burke

http://www.w3.org/2001/XMLSchema#string

John F Neylan

http://www.w3.org/2001/XMLSchema#string

Josep M Campistol

http://www.w3.org/2001/XMLSchema#string

Joseph A Scarola

http://www.w3.org/2001/XMLSchema#string

Martine Gioud-Paquet

http://www.w3.org/2001/XMLSchema#string

Pierre Daloze

http://www.w3.org/2001/XMLSchema#string

Rainer Oberbauer

http://www.w3.org/2001/XMLSchema#string

Rapamune Maintenance Regimen Trial

http://www.w3.org/2001/XMLSchema#string

P304

809-817

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/01.ASN.0000113248.59077.76

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2004-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14978184

http://www.w3.org/2001/XMLSchema#string